KannaLife Sciences Inc

KannaLife Sciences Inc. is a pharmaceutical and phyto-medical company headquartered in Doylestown, Pennsylvania. With a small team of five employees, the company focuses on researching and developing innovative therapeutic agents. Kannalife specializes in creating novel treatments designed to combat oxidative stress, modulate the immune system, and protect the nervous system. Their research and development efforts target a range of conditions including Hepatic Encephalopathy (HE), Chronic Traumatic Encephalopathy (CTE), and Chemotherapy Induced Peripheral Neuropathy (CIPN). The company holds an exclusive license with the National Institutes of Health – Office of Technology Transfer (NIH-OTT) for the commercialization of a US patent related to cannabinoids as antioxidants and neuroprotectants. Kannalife has also developed its own patented molecules, including KLS-13019, which has been dubbed a "super-CBD" by TIME Magazine/SI. For more information about Kannalife Sciences Inc. and its research, visit their website at kannalife.com.